~ FDA Set a PDUFA Target Action Date for PEDMARKTM of August 10, 2020 ~ ~ Strong Financial Position with $38.7 million in cash and no debt ~ Research Triangle Park, NC, August 5, 2020 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation […]
Category: Uncategorized
FENNEC PHARMACEUTICALS ANNOUNCES AMENDMENT TO INCREASE EXISTING SENIOR DEBT FACILITY
Research Triangle Park, NC, June 26, 2020 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced ototoxicity in pediatric patients, today announced an amendment to its existing senior debt facility with the Life Sciences Group at […]
Read More… from FENNEC PHARMACEUTICALS ANNOUNCES AMENDMENT TO INCREASE EXISTING SENIOR DEBT FACILITY
Fennec Announces Results of Annual Meeting
Research Triangle Park, NC — (Marketwired) – June 22, 2020 – Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated May 7, 2020 (the “Circular”) for the Annual General and Special Meeting of Shareholders were elected as directors of the Company at the Annual General […]
Fennec Pharmaceuticals Announces First Quarter 2020 Financial Results and Provides Business Update
~ FDA Set a PDUFA Target Action Date for PEDMARKTM of August 10, 2020 ~ ~ Marketing Authorization Application (MAA) Validated by the EMA in February 2020 ~ ~ Strengthened its Financial Position Through a Raise of Approximately $32 Million in Net Proceeds ~ ~ Commercial Readiness Activities are Underway in the U.S. ~ RESEARCH TRIANGLE PARK, N.C., May 14, 2020 (GLOBE […]
Fennec Announces Exercise and Closing of Underwriters’ Option to Purchase Additional Shares
Research Triangle Park, N.C., May 8, 2020 – Fennec Pharmaceuticals Inc. (Nasdaq: FENC) (TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate ) for the prevention of platinum-induced ototoxicity from cisplatin in pediatric cancer patients, today announced that in connection with its previously completed underwritten offering […]
Fennec Announces Closing of Public Offering
Research Triangle Park, N.C., May 5, 2020 – Fennec Pharmaceuticals Inc. (Nasdaq: FENC) (TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate ) for the prevention of platinum-induced ototoxicity from cisplatin in pediatric cancer patients, today announced the closing of its previously announced underwritten public offering […]
Fennec Announces Pricing of Public Offering
Research Triangle Park, N.C., April 30, 2020 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced ototoxicity from cisplatin in pediatric cancer patients, today announced the pricing of its underwritten public offering of 4,800,000 common shares at […]
Fennec Announces Proposed Public Offering of Common Shares
Research Triangle Park, N.C., April 29, 2020 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced ototoxicity from cisplatin in pediatric cancer patients, today announced that it intends to offer its common shares in an underwritten public […]
Read More… from Fennec Announces Proposed Public Offering of Common Shares
FENNEC PHARMACEUTICALS ANNOUNCES FDA FILING ACCEPTANCE AND PRIORITY REVIEW OF NEW DRUG APPLICATION FOR PEDMARK™
~ Potential for PEDMARK to be the First Product for the Prevention of Cisplatin-Induced Hearing Loss in Children ~ ~ FDA Grants Priority Review and Sets a Prescription Drug User Fee Act (PDUFA) Target Action Date of August 10, 2020 ~ Research Triangle Park, NC, April 13, 2020 – Fennec Pharmaceuticals Inc. (Nasdaq: FENC; TSX: […]
FENNEC ANNOUNCES ISSUANCE OF U.S. PATENT FOR USE OF PEDMARK™
Research Triangle Park, NC, March 5, 2020 – Fennec Pharmaceuticals Inc. (Nasdaq: FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity in pediatric patients, today announced that the U.S. Patent and Trademark Office will issue U.S. Patent 10,596,190 […]
Read More… from FENNEC ANNOUNCES ISSUANCE OF U.S. PATENT FOR USE OF PEDMARK™